Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Drug Cost Cut by 6% by Generic Substitution in 1st Week of April: Nihon Chouzai
April 21, 2008
- New Prescription Form Is Working Well: Mr Takeda
April 21, 2008
- No More Than 10% of Prescriptions Will Be Substituted with Generics: Dr Muto
April 21, 2008
- PMDA Should Support R&D from Patients' Viewpoints: New PMDA Chief Executive
April 21, 2008
- Opinions Split on Whether Only Pharmacists Should Be Allowed to Manage Stores
April 21, 2008
- TOPICS／Q&A Issued on GL on Drugs Using Autologous Cells
April 21, 2008
- OPINION／How to Get Lucky in Your Pharma Career
April 21, 2008
- LDP Begins Discussions on the Need for a Japanese Version of FDA
April 21, 2008
- LDP Proposes Creation of a Japanese Version of FDA
April 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 21, 2008
- Eisai Discontinues Development of E2007 for Parkinson's Disease
April 21, 2008
- Takeda to Acquire Millennium for US$8.8 Billion
April 21, 2008
- Closure of Labs in Japan Consequence of a Natural Course of Events: Dr Kobayashi of PhRMA
April 21, 2008
- Shionogi to Have Own Marketing Forces in US
April 21, 2008
- Council Selects iPS Cells as Priority Technology
April 21, 2008
- Diovan Back to No.1 Position in February: Rep Track Survey
April 21, 2008
- JSRM Calls For Deregulations over Research Using Human ES Cells
April 21, 2008
- BUSINESS NEWS IN BRIEF
April 14, 2008
- JACRI Approves Mid-Term Strategy to Expand Market for Reagents
April 14, 2008
- Mitsuo Sawai to Be Promoted to President of Sawai Pharm.
April 14, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…